See more : Grupo Gicsa S.A.B. de C.V. (GICSAB.MX) Income Statement Analysis – Financial Results
Complete financial analysis of NGM Biopharmaceuticals, Inc. (NGM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of NGM Biopharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Chatham Rock Phosphate Limited (GELGF) Income Statement Analysis – Financial Results
- AUTOWAVE Co., Ltd. (2666.T) Income Statement Analysis – Financial Results
- Bankinvest – Europa Small Cap Aktier KL (BAIESCA.CO) Income Statement Analysis – Financial Results
- Heng Tai Consumables Group Limited (0197.HK) Income Statement Analysis – Financial Results
- INTEGROUP INC (192A.T) Income Statement Analysis – Financial Results
NGM Biopharmaceuticals, Inc. (NGM)
About NGM Biopharmaceuticals, Inc.
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trials for the treatment of non-alcoholic steatohepatitis (NASH); and MK-3655, an agonistic antibody that activates fibroblast growth factor receptor 1c-beta-klotho, which is in Phase IIb clinical trials for use in the treatment of type 2 diabetes and NASH. Its products under development also comprise NGM120, an antagonist antibody that binds GFRAL that is in Phase I/II clinical trials; NGM621, an immunoglobulin 1 monoclonal antibody in Phase II clinical trials for the treatment of geographic atrophy; NGM707, an immunoglobulin-like transcript 2/ immunoglobulin-like transcript 4 dual antagonist monoclonal antibody that is in Phase I/II clinical trials for the treatment of patients with advanced solid tumors; and NGM831 and NGM438 for the treatment of advanced solid tumors. The company has research collaboration, product development, and license agreements with Merck Sharp & Dohme Corp.; and a collaboration agreement with Merck & Co., Inc. to focus primarily on the development of novel medicines for unmet patient needs in retinal and CVM diseases, including heart failure. NGM Biopharmaceuticals, Inc. was incorporated in 2007 and is headquartered in South San Francisco, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4.42M | 55.33M | 77.88M | 87.37M | 103.54M | 108.67M | 77.14M | 85.59M |
| Cost of Revenue | 2.22M | 5.98M | 7.90M | 163.97M | 129.25M | 0.00 | 0.00 | 0.00 |
| Gross Profit | 2.20M | 49.35M | 69.98M | -76.60M | -25.71M | 108.67M | 77.14M | 85.59M |
| Gross Profit Ratio | 49.72% | 89.19% | 89.86% | -87.68% | -24.83% | 100.00% | 100.00% | 100.00% |
| Research & Development | 112.01M | 181.07M | 161.71M | 163.97M | 129.25M | 95.71M | 79.74M | 82.11M |
| General & Administrative | 37.84M | 40.52M | 36.87M | 27.23M | 23.63M | 17.27M | 14.83M | 11.85M |
| Selling & Marketing | -1.11M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 36.74M | 40.52M | 36.87M | 27.23M | 23.63M | 17.27M | 14.83M | 11.85M |
| Other Expenses | -234.00K | -132.00K | -60.00K | -593.00K | -147.00K | 199.00K | -152.00K | 133.00K |
| Operating Expenses | 148.74M | 221.58M | 198.58M | 191.20M | 152.88M | 112.98M | 94.57M | 93.95M |
| Cost & Expenses | 150.96M | 221.58M | 198.58M | 191.20M | 152.88M | 112.98M | 94.57M | 93.95M |
| Interest Income | 9.32M | 3.71M | 420.00K | 1.94M | 6.69M | 3.62M | 2.36M | 1.81M |
| Interest Expense | 0.00 | 3.71M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.22M | 4.04M | 6.09M | 6.56M | 7.61M | 7.22M | 6.44M | 3.53M |
| EBITDA | -144.33M | -166.25M | -120.70M | -103.83M | -49.34M | 2.91M | -10.98M | -4.83M |
| EBITDA Ratio | -3,267.51% | -300.45% | -154.97% | -118.85% | -47.65% | 2.68% | -14.24% | -5.64% |
| Operating Income | -146.55M | -166.25M | -120.70M | -103.83M | -49.34M | -4.31M | -17.43M | -8.36M |
| Operating Income Ratio | -3,317.79% | -300.45% | -154.97% | -118.85% | -47.65% | -3.97% | -22.59% | -9.77% |
| Total Other Income/Expenses | 4.17M | 3.58M | 360.00K | 1.35M | 6.55M | 3.82M | 2.21M | 1.94M |
| Income Before Tax | -142.38M | -162.67M | -120.34M | -102.49M | -42.80M | -493.00K | -15.22M | -6.42M |
| Income Before Tax Ratio | -3,223.34% | -293.98% | -154.51% | -117.30% | -41.33% | -0.45% | -19.73% | -7.50% |
| Income Tax Expense | 0.00 | -3.58M | -6.51M | -8.49M | -14.30M | 3.82M | -1.06M | 500.00K |
| Net Income | -142.38M | -159.09M | -113.83M | -93.99M | -28.50M | -493.00K | -14.16M | -6.92M |
| Net Income Ratio | -3,223.34% | -287.50% | -146.15% | -107.58% | -27.52% | -0.45% | -18.35% | -8.09% |
| EPS | -1.73 | -1.99 | -1.48 | -1.37 | -0.57 | -0.01 | -0.26 | -0.13 |
| EPS Diluted | -1.73 | -1.99 | -1.48 | -1.37 | -0.57 | -0.01 | -0.26 | -0.13 |
| Weighted Avg Shares Out | 82.50M | 79.95M | 77.09M | 68.48M | 50.30M | 64.99M | 53.65M | 53.65M |
| Weighted Avg Shares Out (Dil) | 82.50M | 79.95M | 77.09M | 68.48M | 50.30M | 64.99M | 53.65M | 53.65M |
NGM Bio Presents Phase 1 Safety and Pharmacokinetics Data for NGM621, an Anti-Complement C3 Antibody, in Patients with Geographic Atrophy at the American Academy of Ophthalmology 2020 Virtual
NGM Bio Provides Business Highlights and Reports Third Quarter 2020 Financial Results
NGM Bio to Present at Three Upcoming Investor Conferences
NGM Bio Aldafermin Data, And Other News: The Good, Bad And Ugly Of Biopharma
NGM Biopharmaceuticals (NGM) Investor Presentation - Slideshow
Stocks To Watch: Walmart, Target, Kandi And Gold vs. Bitcoin
Viking Therapeutics: Another Year In Review
NGM Biopharmaceuticals (NYSE:NGM) Director Acquires $13,168.68 in Stock
Barrick Gold: Nevada Gold Mines Update (NYSE:GOLD)
Intercept Pharmaceuticals: Regulatory Snub Unsettles Liver Therapy Front-Runner
Source: https://incomestatements.info
Category: Stock Reports